Acceleron promised they had great data on sotatercept in late January. But was it good enough to justify a doubling of the stock price?
The stock price of Acceleron $XLRN has almost doubled since the biotech announced in late January that its mid-stage study of sotatercept cleared the important endpoints for pulmonary arterial hypertension, or PAH — even though the biotech told investors to wait for the data.
The hard results landed Wednesday afternoon, and now analysts who outlined a potential blockbuster return can start sorting out whether the giddy market response — adding more than $2 billion to the market cap — was warranted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
